A Study of LY3437943 in Participants With Type 2 Diabetes
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 281 participants.
Also called NCT04867785
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 281 participants
- Sponsor
- Registry
-
NCT04867785
-
- Other papers using this trial's data
- Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial
- Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Puerto Rico
- Registry status
- Completed
Technical summary
Registry record NCT04867785. Randomized; double masking; primary purpose treatment. Start 2021-05-13 (actual); primary completion 2022-07-08 (actual). Results posted on 2023-07-03.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of LY3437943 in Participants With Type 2 Diabetes
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- LY3437943
- Intervention (Drug)
- Dulaglutide
- Intervention (Drug)
- Placebo
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct04867785- Content hash
9c2ecff95e7a165e64e74e83f10a74bca83f529b373db4db49472340051e1ccc